

Professor Bev Rowbotham awarded Order of Australia



Congratulations to Sullivan Nicolaides Pathology haematologist Associate Professor Bev Rowbotham, who has been made an Officer in the General Division of the Order of Australia (AO) in the 2019 Australia Day Honours for distinguished service to medicine

through roles with professional associations, to pathology and to medical education.

Professor Rowbotham joined the practice in 1991 and was appointed Director of Haematology in 2000. She is also an Associate Professor of The University of Queensland School of Medicine.

For more than two decades Professor Rowbotham has played a prominent national role in Australian healthcare and, as a respected leader in the medical profession, she holds many key professional, government and board appointments.

Professor Rowbotham said that, while she was honoured to be awarded, she was mindful her achievements were collaborative efforts, adding that she had been fortunate: "I'm humbled – you don't do many things in life by yourself and the recognition is for the fact that I've been part of great teams."

She was most proud of the services provided by the team at Sullivan Nicolaides Pathology: "I've learnt everything I know about the importance of pathology services to patients and their doctors from the people I have worked with here."

Professor Rowbotham was president of the Royal College of Pathologists of Australasia (RCPA), and in 2018 was awarded the RCPA's highest honour, that of Distinguished Fellow. She has five times been elected chair of the Federal Council of the Australian Medical Association, a position she has just stood down from. She has been a ministerial appointment to four Federal Government peak bodies.

"I've really valued the opportunity to speak for pathology and, more broadly, the medical profession in many different settings over the years," she said. "I've done my best to explain pathology – the hidden specialty – to everyone."

One of the areas of work that has given her greatest satisfaction was when, as RCPA President, she advocated for Australia to prepare for genomic medicine. "We're finally getting there – these things take time and you need to play a long game – but we did start that conversation and I'm proud of that work."

More recently, as Chair of the National Pathology Accreditation Advisory Council, she has led a shift from a compliance focus to a risk-based approach, focused on the prevention of patient harm and improving patient safety: "As a haematologist I trained as a clinician and my experiences as a treating doctor have strongly impacted on my thinking – the importance of getting it right so that doctors can rely on pathology results to make their decisions. That really runs throughout everything I've done."

Of particular personal importance is her latest role as Chair of the Avant Mutual Group, Australia's largest medical indemnity provider. "The mutual ethos of doctors looking after doctors is one of my beliefs – it's the way I've lived my life."

She has spent 15 years serving on boards of organisations that provide education and disability services to children. She is currently a Director of AEIOU Foundation for children with autism.

An advocate for good governance, she has established the Bev Rowbotham Doctors on Boards scholarships that are awarded to The University of Queensland medical students to promote governance skills in the next generation of Australia's doctors, and the Pathology Leaders Award through the Royal College of Pathologists of Australasia.

More guided microscopy demonstrations have been added to our Education Video Library

<https://www.snp.com.au/clinicians/education/education-video-library/guided-microscopy/>

Basal cell carcinoma — Non-aggressive types

Dr Jason Gluch, dermatopathologist, gives an introduction into the most common skin tumour, Basal Cell Carcinoma (BCC), in particular the non-aggressive types.



Erythema nodosum

Dr Jill Magee, dermatopathologist, presents a guided microscopy case on Erythema nodosum, a type of panniculitis that presents with red bumps, usually on the lower extremities of young patients (10-30 years old).




Normal Skin

Dr Angus Collins describes the microscopic features of normal skin, including its layers and structures.




Spongiotic dermatitis

Synonyms used by clinicians to describe spongiotic dermatitis include dermatitis and eczematous dermatitis. Dr Blake O'Brien, dermatopathologist at SNP, will talk about the histologic features that define dermatitis as spongiotic, and discuss some of the common causes.



Squamous cell carcinoma


Squamous cell carcinomas (SCCs) are the second most frequently diagnosed carcinoma, behind BCCs. Dr Fiona Lehane reviews cases to provide details of various SCC features, and explores the use of ancillary stains used to assist in the diagnosis of differentiated, moderately differentiated and poorly differentiated tumours.



Leukocytoclastic vasculitis

Two cases of leukocytoclastic vasculitis, also known as hypersensitivity vasculitis, are presented by Dr Jill Magee. Inflammatory changes are described and some of the myriad of causes are considered.





Sonic Skin Pathology Handbook

Update



The Sonic Skin Pathology Handbook has proven to be a highly sought-after reference providing a wealth of up-to-date, authoritative information on a comprehensive range of skin conditions.

We have just released an updated edition, now renamed Skin Pathology in Practice (Volume 1). This includes amendments to four important articles: Melanoma,

Molecular pathways to melanoma, Primary cutaneous lymphoma, and Focus on dermatophytosis.

To obtain a copy of the updated Sonic Skin Pathology in Practice Volume 1, please contact your Medical Liaison Manager.

P 1300 767 284 E education@snp.com.au

Sonic Dx Tips

Simple, fast, intuitive mobile results

Helping you get the most out of your online results app.

A revolution in mobile pathology results reporting, Sonic Dx gives you direct access to Sullivan Nicolaides Pathology's secure database anywhere, anytime.

Sonic Dx's unparalleled functionality allows you to easily customise your reporting workflow to your own needs. To help you get the most out of Sonic DX's amazing capabilities we have produced a series of information sheets.

- Account password recovery
- Cumulative and graphing results
- Dx Plus
- Filters
- Locations
- Patient results history
- Share results



To obtain a copy of any of the information sheets, please contact your Medical Liaison Manager.

P 1300 767 284 E education@snp.com.au

Beacon reproductive carrier screen expands to detect more genes at a reduced price

The Beacon reproductive carrier screen has been expanded and now detects more genes associated with severe childhood-onset genetic disorders. It has been extended from 327 to 402 genes in females and from 299 to 352 for males.

Reproductive carrier screening tests a woman and her partner for the presence of gene mutations which, if present in both, can affect their children through autosomal inheritance. The Beacon screen is designed to identify carriers of autosomal and X-linked recessive disorders that, although rare individually, collectively are more common than the familiar chromosomal disorders such as Down syndrome, for which prenatal screening is widely available and accepted. Although uncommon, these conditions may have serious implications for a family when they occur. Informing a woman of her risk before she becomes pregnant can help her and her partner understand the implications of having a shared genetic mutation.

Price

The price per patient for the Beacon screen of 402 genes (females) or 352 genes (males) has been reduced from \$950 to \$595.* Please note that we do not offer to screen the X-linked genes for unaffected men, as their children are very unlikely to be affected by a mutation in such a gene, hence the lower number of genes detected for men.

Payment is required before the test is performed. Please refer to the request form for payment details. There is no Medicare rebate for carrier screening. If there is a family history of a known mutation, such as Fragile X or cystic fibrosis, the Beacon screen is not the appropriate test.

Turnaround time

Once the sample is received at our laboratory, the results will typically be available within five weeks.

Genetic counselling

Couples tested by us and found to be at high risk of having an affected child will be offered genetic counselling free of charge, upon referral.

Privacy

Samples will be transported to Fulgent Genetics in the USA for analysis and interpretation. This means that patient personal information will be subject to the privacy and data protection rules of Fulgent Genetics in the US, which may be different from those of Australia.

A couple's report will not be produced unless both partners provide consent for their results to be shared with each other and their healthcare provider.

We have a range of resources to help guide you and your patients:

Request form

Information booklet for doctors

Technical bulletin for doctors

Information booklet for patients

More information is available on the Sonic Genetics website:

<https://www.sonicgenetics.com.au/r/cs/beacon/>

